Immune response inducer

Patent metadata

Field	Value
Publication number	US-9504737-B2
Application number	US-73972308-A
Country	US
Kind code	B2
Filing date	Oct 23, 2008
Priority date	Oct 25, 2007
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body. The polypeptides can induce immunity in a living body and cause regression of a tumor in a cancer-bearing living body. Therefore, these polypeptides are especially effective as a therapeutic and/or prophylactic agent for a cancer(s).

First claim

The invention claimed is:

1. A method for exerting an anti-tumor effect, said method comprising administering to a cancer-bearing individual an effective amount of polypeptide (a) or (b) below, said polypeptide having an immunity-inducing activity, or administering to a cancer-bearing individual an effective amount of a recombinant vector, wherein said recombinant vector comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo:
(a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO:16, or SEQ ID NO:18;
(b) a polypeptide having a homology of not less than 95% to SEQ ID NO:16 or SEQ ID NO:18 which has immunity inducing activity,
and wherein said cancer is calmegin-expressing cancer.

2. The method according to claim 1 , wherein said polypeptide (b) has a homology of not less than 98%.

3. The method according to claim 1 , wherein said polypeptide having an immunity-inducing activity has the amino acid sequence shown in SEQ ID NO: 16, or SEQ ID NO:18.

4. The method according to any one of claim 1 , 2 , or 3 , wherein an effective amount of said polypeptide is administered.

5. The method according to claim 1 , wherein said individual is a human, a dog or a cat.

6. The method according to claim 1 , wherein the polypeptide having an immunity-inducing activity has the amino acid sequence shown in SEQ ID NO:16.

7. The method according to claim 1 , wherein the polypeptide having an immunity-inducing activity has the amino acid sequence shown in SEQ ID NO:18.

8. The method according to claim 1 , wherein immunocytes that exert an antitumor effect are induced in said cancer-bearing individual.

9. A method for exerting an anti-tumor effect, said method comprising administering to a cancer-bearing individual an effective amount of polypeptide (a) or (b) below, said polypeptide having an immunity-inducing activity, or administering to an individual an effective amount of a recombinant vector, wherein said recombinant vector comprises a polynucleotide encoding said polypeptide and is capable of expressing said polypeptide in vivo:
(a) a polypeptide comprising the amino acid sequence shown in SEQ ID NO:16;
(b) a polypeptide having a homology of not less than 95% to SEQ ID NO:16 which has immunity inducing activity.

10. The method according to claim 1 , further comprising administering an immunoenhancer.

11. The method according to claim 10 , wherein said immunoenhancer is at least one selected from the group consisting of: Freund's incomplete adjuvant; Montanide; poly I:C and derivatives thereof; CpG oligonucleotides; interleukin-12; interleukin-18; interferon-α; interferon-β; interferon-ω; interferon-γ; and Flt3 ligand.

Assignees

• Ishibashi Masaki
• Okano Fumiyoshi
• Toray Industries

Inventors

• Ishibashi Masaki
• Okano Fumiyoshi

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61K38/212

  IFN-alpha · CPC title